Civetta Therapeutics was founded to advance new medicines through small molecule targeting of beta-propeller domains with the goal of developing important therapeutics for cancers and other diseases.
Propeller proteins are structural scaffolds that mediate protein-protein interactions of unique substrates. These proteins are found ubiquitously across cell types and can have diverse functional roles in the pathogenesis of cancer, neurodegeneration, metabolic disease and other areas.
Our vision is to build a portfolio of therapeutics by integrating a broad range of expertise in drugging the propeller domains spanning from biochemistry to biology to medicinal chemistry. These efforts will support the creation of near term therapeutics and longer term value in becoming a leader in this space.